PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
Open accessThe DOI matches its Crossref record; 143 of the 144 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
In the last decade, pathway-specific targeted therapy has revolutionized colorectal cancer (CRC) treatment strategies. This type of therapy targets a tumor-vulnerable spot formed primarily due to an alteration in an oncogene and/or a tumor suppressor gene. However, tumor heterogeneity in CRC frequently results in treatment resistance, underscoring the need to understand the molecular mechanisms involved in CRC for the development of novel targeted therapies. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of the rapamycin (PI3K/Akt/mTOR) signaling pathway axis is a major pathway altered in CRC. The aberrant activation of this pathway is associated with CRC initiation, progression, and metastasis and is critical for the development of drug resistance in CRC. Several drugs target PI3K/Akt/mTOR in clinical trials, alone or in combination, for the treatment of CRC. This review aims to provide an overview of the role of the PI3K/Akt/mTOR signaling pathway axis in driving CRC, existing PI3K/Akt/mTOR-targeted agents against CRC, their limitations, and future trends.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Activating mutations in PIK3CA can also contribute to resistance to anti-EGFR therapy in KRAS-WT CRC patients by persistent activation of the PI3K/AKT/mTOR signaling pathway [126].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“While PI3K pathway inhibitors as a monotherapy have not shown significant antitumor effects in treating CRC, their utility in combination therapy is actively being studied.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“Various drugs targeting this pathway are under investigation for CRC treatment, including pan-PI3K inhibitors, isoform-specific PI3K inhibitors, dual PI3K-mTOR inhibitors, Akt inhibitors, and mTOR inhibitors [126].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · cited 2×
“…in both the cytoplasm and nucleus, including the Bcl2-associated agonist of cell death (BAD), forkhead box O (FOXO), glycogen synthase kinase 3 (GSK3), the Full Akt activity is achieved through phosphorylation at the Serine 473 residue in the C-terminal hydrophobic motif by mTORC2 [17].”
BackgroundAKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 4×
“Compared with other PI3K pathway inhibitors, dual PI3K/mTOR inhibitors can inhibit all PI3K catalytic isoforms, mTORC1, and mTORC2 [80] and should block this pathway completely and overcome the feedback inhibition observed with mTORC1 inhibitors (i.e., rapamycin analogs).”
BackgroundInfluentialColorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · cited 5×
“The PI3K/Akt/mTOR pathway axis is critical for cell survival, proliferation, and growth, and it is one of the most frequently altered pathways in human cancer, making it a promising target for cancer therapy [9–12].”
BackgroundInfluential
Cited by
PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment
Jiang, M., Zhang, K., Zhang, Z., Zeng, X., Huang, Z., Qin, P., Xie, Z., Cai, X., Ashrafizadeh, M., Tian, Y., et al. (2025) · MedComm · doi:10.1002/mco2.70295 · Cited by 235
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Various drugs targeting this pathway are under investigation for CRC treatment, including pan-PI3K inhibitors, isoform-specific PI3K inhibitors, dual PI3K-mTOR inhibitors, Akt inhibitors, and mTOR inhibitors [126].”
Research on the role and mechanism of the PI3K/Akt/mTOR signalling pathway in osteoporosis
Liu, C., Zhang, J., Ye, Z., Luo, J., Peng, B., & Wang, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1541714 · Cited by 76
Zhang, H., Tang, J., Cao, H., Wang, C., Shen, C., & Liu, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119007 · Cited by 27
Razzaq, S., Fatima, I., Moafian, Z., Rahdar, A., Fathi‐karkan, S., Kharaba, Z. J., Shirzad, M., Khan, S. A., & Pandey, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02670-z · Cited by 28
Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer
Hashemi, M., Khosroshahi, E. M., Asadi, S., Tanha, M., Mohseni, F. G., Sagha, R. A., Taheri, E., Vazayefi, P., Shekarriz, H., Habibi, F., et al. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.08.002 · Cited by 30
Monge, C., Waldrup, B., Carranza, F., & Velazquez-Villarreal, E. I. (2025) · Cancers · doi:10.3390/cancers17071093 · Cited by 16
Genetic Insights into Colorectal Cancer: Evaluating PI3K/AKT Signaling Pathway Genes Expression
Świechowski, R., Pietrzak, J., Wosiak, A., Mik, M., & Balcerczak, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115806 · Cited by 25
Xie, J., Li, D., Niu, S., Sheng, Y., Shen, R., He, Y., Xu, C., Zhang, Y., Wang, T., & Xue, Y. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401009 · Cited by 20
Duta-Ion, S. G., Juganaru, I. R., Hotinceanu, I. A., Dan, A., Burtavel, L. M., Coman, M. C., Focșa, I. O., Zaruha, A.-G., Codreanu, P. C., Bohîlțea, L. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312507 · Cited by 25
Clinical Investigation of Tyrosinase Inhibitors: Past, Present, and Future
Wang, Y. Y., Jiang, R., Xiong, B., Zhu, J., Sang, J., Li, H., Chen, C., Xu, Z., Zhang, W., Chen, Y., et al. (2025) · Drug Development Research · doi:10.1002/ddr.70113 · Cited by 19
Sun, Y.-H., Zhang, J.-X., Jin, H.-S., & Huang, J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090751 · Cited by 14
Jia, M., Yuan, Z., Yu, H., Feng, S., Tan, X., Long, Z., Duan, Y., Zhu, W., & Yan, P. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116883 · Cited by 17
METTL1 Enhances RRP9 mRNA Stability Through m7G Modification to Drive Colorectal Tumorigenesis
Li, N., Jing, Y., Xu, L., & Wang, M. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23892 · Cited by 15
Nanozyme for precision treatment of hepatocellular carcinoma
Feng, S., Xuan, Y., Jin, H., Cui, M., Meng, X., Liao, J., & Feng, J. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102840 · Cited by 22
Chidananda, C., Thakur, G., Datta, D., & Popat, K. C. (2025) · 3 Biotech · doi:10.1007/s13205-025-04535-8 · Cited by 12
Sultan, M. H., Zhang, Q., Wang, Y., Xia, Y., & Jia, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5545 · Cited by 11
Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors
Zhao, K., Zhang, J., Zhou, L., & Sun, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1483785 · Cited by 13
Ahamed, M. S., & Ashik, S. A. A. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110441 · Cited by 11
Molavand, M., Montazer, M., Ghareghomi, S., Yousefi, B., & Majidinia, M. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2519860 · Cited by 13
Yang, E.-W., Waldrup, B., & Velazquez-Villarreal, E. (2025) · medRxiv · doi:10.3390/ijms26136487 · Cited by 5
Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances
Chen, Y., Zhang, J., Ding, Y., Zhu, F., & Chen, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00433-4 · Cited by 17
Palenca, I., Franzin, S. B., Zilli, A., Seguella, L., Troiani, A., Pepi, F., Vincenzi, M., Giugliano, G., Catapano, V., Filippo, I. D., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8303 · Cited by 9
The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors
Li, P., Ma, X., & Gu, X. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1442193 · Cited by 10
Banu, H., Al-Shammari, E., Shahanawaz, S., Azam, F., Patel, M. B., Alarifi, N. A., Ahmad, M. F., Adnan, M., & Ashraf, S. A. (2025) · Pharmaceuticals · doi:10.3390/ph18040453 · Cited by 9
Liu, W., Zheng, D., Huang, X., Wei, Z., Wei, Z., & Guo, W. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08070-5 · Cited by 10
SERPINE1 drives molecular synergies in colorectal cancer
Nuha, N., Higgins, S. P., Czekay, R., Higgins, C. E., Guo, L., Lee, H., & Higgins, P. J. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00759.2025 · Cited by 11
Leiphrakpam, P. D., Batra, R., Tenner, L. L., & Are, C. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl39100 · Cited by 12
Self-citationDecoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI
Cataldi, C., Karaoğlan, B. B., Liotta, E., & Dosso, S. D. (2026) · Cancers · doi:10.3390/cancers18050852 · Cited by 11
Nucleolar protein 3 promotes proliferation of bladder cancer cells through the PI3K-Akt pathway
Wu, L., Zhu, K., Sun, Y., Li, T., Zhu, J., Tong, H., Zhang, X., Chen, J., Yin, H., & He, W. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03600-5 · Cited by 11
Lasota, J. P., Kaczorowski, M., Chłopek, M., Miłek-Krupa, J., Szczepaniak, M., Ylaya, K., Chodyna, M., Iżycka‐Świeszewska, E., Scherping, A. K., Czapiewski, P., et al. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105717 · Cited by 8
Yang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39857 · Cited by 9
Mousavikia, S. N., Matin, M. M., Tossi, M. T. B., Aghaee‐Bakhtiari, S. H., & Azimian, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-14501-5 · Cited by 10
Clinical and genetic drivers of oligo-metastatic disease in colon cancer
Ottaiano, A., Santorsola, M., Sirica, R., Mauro, A. D., Carlo, A. D., Ianniello, M., Sabbatino, F., Castiello, R., Peschio, F. D., Cascella, M., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101111 · Cited by 6
Du, H.-F., Jiang, J.-M., Wu, S.-H., Shi, Y.-F., Liu, H.-T., Hua, Z.-H., Wang, C., Qian, G.-Y., & Ding, H. (2024) · Molecules · doi:10.3390/molecules29153603 · Cited by 9
Qian, Y., Zhu, D., Qiong, X., Wang, Y., Chen, X., Hua, W., Xi, J., & Lu, F. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114492 · Cited by 6
Prognostic gene expression profile of colorectal cancer
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Baldaniya, L., Ballal, S., Vashishth, R., Parmar, M., Sameer, H. N., Hamad, A. K., Athab, Z. H., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149433 · Cited by 6
Zhou, X., Jiang, J., Liu, J., Wang, Q., Luo, Y., & Wu, L. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1620723 · Cited by 12
Advances and challenges in drug repurposing in precision therapeutics of colorectal cancer
Yu, X., Wu, H.-T., Wu, B., Zhi, S.-F., Lan, Y.-Z., Chen, W.-J., & Liu, J. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i7.107681 · Cited by 9
Leung, H. K. M., Lo, E. K. K., Chen, C., Zhang, F., Felicianna, Ismaiah, M. J., & El-Nezami, H. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-11820-2 · Cited by 5
Dai, Y., Huang, X., Sun, M., Zhang, S., Yu, W., Hu, K., Wu, Q., & Wu, Q. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1615259 · Cited by 6
Hu, J., Tang, Z., Beeraka, N. M., Xu, R., Liu, J., Zhao, X., Li, L., Wang, R., Gayathri, T., Padmanabha Reddy, Y., et al. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2600679 · Cited by 6
Zheng, L., Zhang, H., & Sun, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0339565 · Cited by 5
Qi, H., Cao, M., Chen, Y., Li, X., Wang, Y., Dai, X., Duan, X., & Lü, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113257 · Cited by 6
The Inositol-5-Phosphatase SHIP1: Expression, Regulation and Role in Acute Lymphoblastic Leukemia
Ehm, P. A. H., & Jücker, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146935 · Cited by 5
Li, J., Shen, X., Sun, C., Hou, Y., Hu, Y., Ma, S., Huang, L., Ma, L., Zhang, Y.-B., & Dai, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155745 · Cited by 5
KIFC3 promotes the progression of non–small cell lung cancer cells through the PI3K/Akt pathway
Mu, Y., Liu, H., Luo, A., & Zhang, Q. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15465 · Cited by 4
Tom, V. V., José, A. D. L. F. H., Mallick, S., Sasidharan, A., Pawar, R., Somayaji, Y., & Fernandes, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03985-4 · Cited by 5
Dong, Z., She, X., Ma, J., Chen, Q., Gao, Y., Chen, R., Qin, H., Shen, B., & Gao, H. (2025) · Advanced Science · doi:10.1002/advs.202504704 · Cited by 9
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
“These agents have not shown sufficient benefit to progress to successful phase III development in unselected CRC populations, underscoring the need for improved biomarker-driven patient selection and rational combination strategies [139].”
Yu, K., Yao, Y., Zhang, C., & Hao, L. (2025) · CytoJournal · doi:10.25259/cytojournal_200_2024 · Cited by 5
Multi Omics Integration in Colorectal Cancer: From Molecular Insights to Precision Oncology
Liu, Z., Ang, M. Y., & Kue, C. S. (2026) · Cancers · doi:10.3390/cancers18101504 · Cited by 6
Li, Y., Wang, Y., Wu, R., Li, P., & Cheng, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-63896-x · Cited by 5
Voutsadakis, I. A. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20470 · Cited by 5
Delgado-Waldo, I., Dokudovskaya, S., Loissell-Baltazar, Y. A., Pérez-Arteaga, E., Coronel-Hernández, J., Martínez‐Vázquez, M., Pérez-Yépez, E.-A., Saavedra, A. L., Jacobo-Herrera, N. J., & Pérez‐Plasencia, C. (2024) · Cells · doi:10.3390/cells13191649 · Cited by 5
Wang, Z., Li, T., Sun, M., Liu, N., Zhang, H., Feng, Z., & Lei, N. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00010 · Cited by 5
Sharma, D., & Arumugam, S. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111068 · Cited by 5
Wang, Z., Yue, X., Feng, S., Li, J., Wang, S., Lan, X., Li, Z., Wang, L., Li, Z., & Yang, B. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120517 · Cited by 4
GCSH promotes colorectal cancer progression by inhibiting Cuproptosis through the PI3K/AKT-FDX1 axis
Guo, X., Li, J., Shen, L., Ding, Z., & Lei, R. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01808-6 · Cited by 4
Xu, L., Ning, J., Wang, J., Jiang, P., Zhang, X. H., & Cheng, F. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111218 · Cited by 4
Personalised medicine based on host genetics and microbiota applied to colorectal cancer
González, A., Badiola, I., Fullaondo, A., Rodríguez, J., & Odriozola, A. (2024) · Advances in genetics · doi:10.1016/bs.adgen.2024.08.004 · Cited by 4
Urea and Thiourea Derivatives of Salinomycin as Agents Targeting Malignant Colon Cancer Cells
Antoszczak, M., Mielczarek‐Puta, M., Struga, M., & Huczyński, A. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206322603241002064435 · Cited by 4
Yousefi, B., Valizadeh, A., Molavand, M., & Majidinia, M. (2024) · Studies in Medical Sciences · doi:10.61186/umj.35.6.467 · Cited by 5
Hussein, M. A., Farouk, G. A., Abdelkader, H. K., Daniel, M. A., Youssef, M. A., Eldesoky, G. E., Alam, S. M., Islam, M. S., & Mosaad, Y. O. (2025) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928361989250226083146 · Cited by 4
Dang, W., Wu, S., Liu, X., Shen, H., Chen, Y., Zhang, Z., Wang, H., Cai, Z., Li, M., Sun, M., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13338-8 · Cited by 6
Hou, H.-P., Liu, X., Liu, W., Zhang, P., & Zhou, B. (2025) · Medical Oncology · doi:10.1007/s12032-025-02699-0 · Cited by 3
Zeki, N. M., & Mustafa, Y. F. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162024607225 · Cited by 4
Ho, P.-Y., Koh, Y., Lin, W., Ho, C., Majeed, A., Ho, C., & Pan, M. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c05807 · Cited by 5
Feng, S., Peng, C., Zou, D., Wen, S., Hu, B., Zhu, S., Du, Y., & Shen, B. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206437150251113065146 · Cited by 4
Wu, P., Yao, P., Zhao, M., & Cheng, M. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08138-2 · Cited by 5
Zhao, Z.-Q., Yu, Z.-X., Liu, Z.-Q., Yu, T., & Fan, H. (2026) · Current Medical Science · doi:10.1007/s11596-026-00201-z · Cited by 3
Panx3 mediates ferroptosis via the AKT/mTOR signaling pathway in oral squamous cell carcinoma
Li, X., Zhao, Y., Liu, Y., Zhang, C., Xu, Z.-Y., Wang, S.-R., Zhang, T.-M., Zhang, Y., Liang, S.-X., & Yan, Y. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111908 · Cited by 3
Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma
Shao, W., Yan, F., Huang, J., Li, T., Gao, S., Yang, Y., Li, D., Yang, Z., & Yao, Z. (2024) · Open Life Sciences · doi:10.1515/biol-2022-0936 · Cited by 3
Advances in the design, discovery, and optimization of aurora kinase inhibitors as anticancer agents
Verma, A., Bharatiya, P., Jaitak, A., Nigam, V., & Monga, V. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2481272 · Cited by 3
Bischoff, N. S., Undas, A. K., van Herwijnen, M. H. M., Verheijen, M. C. T., Briedé, J. J., Breda, S. G. J. V., Sijm, D. T. H. M., & de Kok, T. M. C. M. (2025) · Toxicology in Vitro · doi:10.1016/j.tiv.2025.106105 · Cited by 3
Proteomics-Enhanced AI-Digital Pathology in Metastatic Mucinous Colorectal Carcinoma: A Case ReportPreprint
Fülöp, L., Szigeti, B., Guedes, J. S., Woldmar, N., Oskolás, H., Marko-Varga, M., Appelqvist, R., Wieslander, E., Pawlowski, K., Szadai, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.02.709044 · Cited by 3
Feng, H., Zhang, Y., Shen, L., Wang, H., Qiu, L., Xiaoyu, Y., & Jiang, H. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01592-8 · Cited by 2
He, W., & He, L. (2025) · Pharmacognosy Magazine · doi:10.1177/09731296251329683 · Cited by 2
Wang, C., Chen, Y., Wang, Z., Zhou, T., Zhou, Y., Li, Y., Fan, Y., & Shi, Q. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130437 · Cited by 2
Zhang, R., Yin, X., Xu, Z., & Yan, Q. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214576 · Cited by 2
Cao, X., Zhou, J., Sun, H., Wang, J., Wang, X., Xiang, X., Shi, X., Ye, B., Chu, X., Li, X., et al. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.147568 · Cited by 3
Abenavoli, L., Scarlata, G. G. M., Gambardella, M. L., Morano, D., Milošević, N. V., Milanović, M., & Milić, N. (2026) · Diseases · doi:10.3390/diseases14010033 · Cited by 2
Targeting cell death: a promising approach for colorectal cancer therapy
Xiao, C., Oyang, L., Jiang, X., Li, S., & Peng, Q. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04261-y · Cited by 3
Nidhi, Sushma, Singh, A., & Chundawat, T. S. (2026) · ChemistrySelect · doi:10.1002/slct.73810 · Cited by 2
Aiyejuto, D., Luthria, A., Hui, T., & Shenoy, A. K. (2026) · Cancers · doi:10.3390/cancers18162569 · Cited by 2
Thảo, Đ. T., Thanh, N. P., Quyền, Đ. V., Khai, L. T., Le, S. H., & Trung, N. T. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309209 · Cited by 2
Lin, L., Wen, J., Xu, T., & Si, Y. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2424570 · Cited by 2
Zhang, X., Li, Z., & Wang, T. (2024) · Cytotechnology · doi:10.1007/s10616-024-00661-y · Cited by 2
Leptin increases chemosensitivity by inhibiting CPT1B in colorectal cancer cells
Mi, X., Yao, H., Lu, Y., Yang, M., Yang, Y. A., Fang, D., & He, S. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2024-950 · Cited by 2
Zhang, G., Zhang, Z., & Zhou, Y. (2025) · International Journal of Colorectal Disease · doi:10.1007/s00384-025-04896-9 · Cited by 2
Innovative dual-target AKT inhibitors unveiling novel mechanisms and translational potential
Yan, S. Z., Wang, L., Liu, D., Qin, H., Du, C., Chai, J., Liu, Y., Chen, Y., Liu, H., & Jin, T. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108774 · Cited by 2
Stecko, H., Tsilimigras, D. I., Iyer, S., Daw, J., Zhu, H., Huang, E., Kalady, M. F., & Pawlik, T. M. (2025) · Surgery · doi:10.1016/j.surg.2025.109475 · Cited by 3
Jiang, Y., Li, J., Qiu, J., Zhou, Y., Lai, Y., & Yang, W. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01809-z · Cited by 1
ITGA5 drives glioblastoma progression through SLK-mediated activation of the PI3K-Akt pathway
Hu, H., Fan, X., Wei, J., Wang, G., Li, Y., Lu, C., Lin, Y., Bao, Y. W., Jiang, L., & Hou, L. (2025) · Neurological Research · doi:10.1080/01616412.2025.2512437 · Cited by 1
Khani, M., Latifi, A., & Sayyadi, M. (2025) · Iranian Biomedical Journal · doi:10.61882/ibj.5031 · Cited by 2
Shamsudin, N. F., Nawi, A. R. M., Jantan, I., Salim, E., Abdullah, M. A., Chia, S. L., Saad, N., Imran, S., Leong, S. W., Nainu, F., et al. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102601 · Cited by 3
Cui, C., Hong, M., Zhao, H., Wang, L., Yang, Y., Wang, J., & Sun, L. J. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114732 · Cited by 1
Niu, F., Ren, Y., Li, Y., Li, Z., Li, Z., Wang, J., Yu, Y., Zheng, A., Li, X., & Xiong, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117446 · Cited by 2
Zhu, Y., Tang, Z., Lu, Z., Gao, D., Pan, H., Jiang, H., Zhang, Z., & Zhang, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1698721 · Cited by 1
Paeoniflorin suppresses non-small cell lung cancer by interrupting FGF2-FGFR2-PI3K axis
Shao, X., Ding, B., Gao, M., Li, J., Shi, Y., Chen, S., Shahen, M., Wang, Y., & Li, Y. (2025) · Toxicon · doi:10.1016/j.toxicon.2025.108651 · Cited by 1
Metadata
- Authors
- Leiphrakpam, P., & Are, C.
- Affiliations
- University of Nebraska Medical Center (US)
- Corresponding author
- Leiphrakpam, Premila
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-03-09
- Volume
- 25
- Issue
- 6
- Pages
- 3178
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10970097
- OpenAlex
- W4392661434
- Cited by
- 193
- References
- 144
- Citations by year
- 2026: 82 · 2025: 82 · 2024: 29
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- colorectal cancer, PI3K/AKT/mTOR pathway, targeted therapy, drug resistance, tumor heterogeneity, metastasis, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, combination therapy
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Humans, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.